# BicycleTX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bicycletx

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.bicycletherapeutics.com
- Total disclosed funding: $51M
- Latest round: Series B (Jun 1, 2017)
- Investors on record: 7

## About

BicycleTX Limited is a UK-based biopharmaceutical company focused on developing precision-guided therapeutics for solid tumors and other conditions. Its innovative technology targets hard-to-reach cancer cells, addressing significant medical needs across various therapeutic areas.BicycleTX Limited specializes in precision therapeutics to treat solid tumors and expand into related applications. Founded in 2009 in Cambridge, UK, the company has raised USD 200.00 mn over several funding rounds, with the most recent being a Private Placement on July 12, 2023. The CEO, Kevin Lee, has a background in leading biotechnology firms, enhancing BicycleTX's strategic direction and partnerships.Bicycle Therapeutics focuses on developing precision-guided therapeutics aimed primarily at treating solid tumors while exploring applications in anti-infective, cardiovascular, ophthalmology, dementia, central nervous system, neuromuscular, and respiratory conditions. Their Bicycle® molecules are designed to penetrate tissues and target difficult cancer cells, collaborating with healthcare providers and pharmaceutical partners in North America and Europe to enhance therapeutic development.In 2023, BicycleTX Limited reported revenues of USD 25.86 mn, with an EBITDA of USD -194.73 mn. The company generates revenue through strategic partnerships and collaborations, engaging in research and development agreements, licensing deals, and co-development partnerships to advance its therapeutic candidates.BicycleTX Limited plans to leverage its recent funding of USD 200.00 mn from a Private Placement in July 2023 to support the development of new therapeutics targeting various conditions. The company aims to expand its market reach in North America and Europe, focusing on launching innovative products within the next two years. Recent funding will enable BicycleTX to enhance its partnerships with academic and pharmaceutical institutions, ensuring the advancement of its therapeutic candidates and addressing the unmet medical needs in oncology and beyond.

## Funding rounds

- Series B, Jun 1, 2017, $51M — Atlas Venture, Novartis Venture Fund, SR One, SV Health Investors, Longwood Fund, Cambridge Innovation Capital, Vertex Ventures HC
- Seed, Dec 1, 2009 — SR One, SV Health Investors
- Seed, Oct 7, 2009 — Atlas Venture, Novartis Venture Fund

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed, Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Seed, Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed, Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series B
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series B